FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific MOST POPULAR Mom Is Warning Other Parents After Her Son Was Bit By... May 24, 2019 England moves to a single-dose HPV vaccine June 21, 2023 EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin August 18, 2025 The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem January 6, 2022 Load more HOT NEWS ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with... Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type...
